Literature DB >> 19505284

Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects.

Jason H Karnes1, Rhonda M Cooper-DeHoff.   

Abstract

Blood pressure reduction is associated with significant reduction in adverse cardiovascular outcomes. Certain blood pressure-lowering drugs have adverse effects on glucose homeostasis, and have been associated with the development of both prediabetes and diabetes during use. There is controversy over the significance of diabetes that develops during treatment with antihypertensives and whether the benefits of blood pressure reduction offset the hazards of dysglycemia that can lead to diabetes. Many treatment guidelines have recently undergone revisions to include consideration for the metabolic effects of antihypertensive drugs, particularly in high-risk populations. This review summarizes the data related to the benefits of blood pressure reduction as well as the adverse metabolic effects and new-onset diabetes associated with some medications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19505284      PMCID: PMC2799117          DOI: 10.1586/erc.09.31

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  125 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication.

Authors:  Ajay K Gupta; Bjorn Dahlof; Joanna Dobson; Peter S Sever; Hans Wedel; N R Poulter
Journal:  Diabetes Care       Date:  2008-01-30       Impact factor: 19.112

Review 3.  Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance.

Authors:  E J Henriksen; S Jacob
Journal:  Diabetes Obes Metab       Date:  2003-07       Impact factor: 6.577

4.  A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus.

Authors:  Sripal Bangalore; Sanobar Parkar; Ehud Grossman; Franz H Messerli
Journal:  Am J Cardiol       Date:  2007-08-10       Impact factor: 2.778

5.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

6.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

7.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

Authors:  Marcus D Flather; Marcelo C Shibata; Andrew J S Coats; Dirk J Van Veldhuisen; Aleksandr Parkhomenko; Joszef Borbola; Alain Cohen-Solal; Dan Dumitrascu; Roberto Ferrari; Philippe Lechat; Jordi Soler-Soler; Luigi Tavazzi; Lenka Spinarova; Jiri Toman; Michael Böhm; Stefan D Anker; Simon G Thompson; Philip A Poole-Wilson
Journal:  Eur Heart J       Date:  2005-01-09       Impact factor: 29.983

9.  Diabetes mellitus and raised serum triglyceride concentration in treated hypertension--are they of prognostic importance? Observational study.

Authors:  O Samuelsson; K Pennert; O Andersson; G Berglund; T Hedner; B Persson; H Wedel; L Wilhelmsen
Journal:  BMJ       Date:  1996-09-14

Review 10.  Is new-onset diabetes of clinical significance in treated hypertensive patients?--Con.

Authors:  Marvin Moser
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-02       Impact factor: 3.738

View more
  12 in total

Review 1.  Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity.

Authors:  Valentina Medici; Stephen A McClave; Keith R Miller
Journal:  Curr Gastroenterol Rep       Date:  2016-01

2.  Visually guided classification trees for analyzing chronic patients.

Authors:  Cristina Soguero-Ruiz; Inmaculada Mora-Jiménez; Miguel A Mohedano-Munoz; Manuel Rubio-Sanchez; Pablo de Miguel-Bohoyo; Alberto Sanchez
Journal:  BMC Bioinformatics       Date:  2020-03-11       Impact factor: 3.169

3.  Alteration in fasting glucose after prolonged treatment with a thiazide diuretic.

Authors:  Jason H Karnes; Yan Gong; Meghan J Arwood; John G Gums; Karen L Hall; Marian C Limacher; Julie A Johnson; Rhonda M Cooper-DeHoff
Journal:  Diabetes Res Clin Pract       Date:  2014-04-13       Impact factor: 5.602

Review 4.  Anti-hypertensive drugs in children and adolescents.

Authors:  Patricia Y Chu; Michael J Campbell; Stephen G Miller; Kevin D Hill
Journal:  World J Cardiol       Date:  2014-05-26

5.  Influence of pharmacological therapies on vascular function and urinary sodium/potassium excretion.

Authors:  Michelle Rabello Cunha; Mario Fritsch Neves
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-01-08       Impact factor: 3.738

6.  The metabolic cost of lowering blood pressure with hydrochlorothiazide.

Authors:  Angela L Price; Ildiko Lingvay; Edward W Szczepaniak; Jaime Wiebel; Ronald G Victor; Lidia S Szczepaniak
Journal:  Diabetol Metab Syndr       Date:  2013-07-09       Impact factor: 3.320

7.  Systolic Blood Pressure and Risk of Type 2 Diabetes: A Mendelian Randomization Study.

Authors:  Rachael C Aikens; Wei Zhao; Danish Saleheen; Muredach P Reilly; Stephen E Epstein; Emmi Tikkanen; Veikko Salomaa; Benjamin F Voight
Journal:  Diabetes       Date:  2016-10-04       Impact factor: 9.461

8.  A retrospective longitudinal cohort study of antihypertensive drug use and new-onset diabetes in Taiwanese patients.

Authors:  Ching-Ya Huang; Tsochiang Ma; Liyun Tien; Yow-Wen Hsieh; Shwu-Yi Lee; Hung-Yi Chen; Gwo-Ping Jong
Journal:  Biomed Res Int       Date:  2012-12-23       Impact factor: 3.411

9.  Antihypertensive drug class interactions and risk for incident diabetes: a nested case-control study.

Authors:  Rhonda M Cooper--DeHoff; Steven T Bird; Gregory A Nichols; Joseph A Delaney; Almut G Winterstein
Journal:  J Am Heart Assoc       Date:  2013-06-10       Impact factor: 5.501

10.  Comorbidity Status and Annual Total Medical Expenditures in U.S. Hypertensive Adults.

Authors:  Chanhyun Park; Jing Fang; Nikki A Hawkins; Guijing Wang
Journal:  Am J Prev Med       Date:  2017-12       Impact factor: 5.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.